BioSyent Releases Q3 and YTD 2021 Financial Results

MISSISSAUGA, Ontario, Nov. 18, 2021 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2021. Key highlights include: Third quarter (Q3) 2021 Net Revenues of $6,690,419 increased by 16% versus Q3 2020Year-to-date (YTD) 2021 Net Revenues of $21,399,562 increased by 29% versus YTD 2020Canadian Pharmaceutical Net Revenues in Q3 2021 of $6,409,809 increased by 17% versus Q3 2020YTD 2021 Canadian Pharmaceutical Net Revenues of $19,313,894 increased by 22% versus YTD 2020Q3 2021 International Pharmaceutical Net Revenues of $Nil as compared to $6,306 in Q3 2020YTD 2021 International Pharmaceutical Net Revenues of $1,305,317 increased by 675% versus YTD 2020Q3 2021 EBITDA1 of $2,293,713 increased by 64% versus Q3 2020YTD 2021 EBITDA1 of $6,144,581 increased by 38% versus YTD 2020Q3 2021 Net Income After Taxes (NIAT) of $1,721,320 increased by 80% versus Q3 2020YTD 2021 NIAT of $4,403,762 increased by 41% versus YTD 2020Q3 2021 NIAT percentage to Net Revenues of 26% compares to 17% in Q3 2020YTD 2021 NIAT percentage to Net Revenues of 21% compares to 19% in YTD 2020Q3 2021 Fully Diluted EPS of $0.13 was $0.06 higher than Q3 2020 Fully Diluted EPS of $0.07YTD 2021 Fully Diluted EPS of $0.34 was $0.10 higher than YTD 2020 Fully Diluted EPS of $0.24Fully Diluted EPS for the Trailing Twelve Months ended September 30, 2021 was $0.39 as compared to $0.32 for the Trailing Twelve Months ended September 30, 2020As at September 30, 2021, the Company had cash, cash equivalents, and short-term investments totalling $27,101,933, a 6% increase as compared to $25,577,706 as at December 31, 2020Total Shareholders’ Equity increased by 13% to $30,332,390 at September 30, 2021 from $26,795,956 at December 31, 2020Return on Equity for the Trailing Twelve Months ended September 30, 2021 was 18% as compared to 17% for the Trailing Twelve Months ended September 30, 2020During YTD 2021, repurchased and cancelled a total of 79,700 common shares under a Normal Course Issuer Bid (NCIB) “Q3 2021 marked BioSyent’s 45th consecutive profitable quarter as well as its most profitable quarter to date with record NIAT of $1,721,320 increasing by 80% over Q3 2020. Our established Canadian pharmaceutical brands, led by FeraMAX® Pd, continued to drive topline growth and profitability while we continued to invest in launch brands, resulting in a healthy 26% net profit margin overall in the quarter. Together with growth contributed by launch brands, Tibella® and Combogesic®, Canadian pharmaceutical sales showed double-digit growth overall for the quarter as we navigated through the ongoing impacts of COVID-19 on the business and healthcare environments in Canada,” commented Mr. René Goehrum, President and CEO of BioSyent. “We generated $2.3 million of cash during Q3 2021 and have maintained our commitment to our NCIB, having bought back 142,650 shares to date during 2021. In October of this year, we launched FeraMAX® Pd Powder 15, the second product using the patented PDIC oral iron delivery system, following on the success of FeraMAX® Pd Therapeutic 150, launched in November 2020. We are planning for further innovative FeraMAX® Pd product extensions while we continue to invest in our launch brands and future additions to our product portfolio.”           The CEO’s presentation on the Q3 2021 Results is available at the following link: www.biosyent.com/q3-21/. The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management’s Discussion and Analysis for the three and nine months ended September 30, 2021 and 2020 will be posted on www.sedar.com on November 18, 2021. Q3 2021 Interim Financial Statements PDF available at: http://ml.globenewswire.com/Resource/Download/222ed00f-b757-4727-becb-1538d0102244 Q3 2021 MD&A PDF available at: http://ml.globenewswire.com/Resource/Download/80248e90-986e-49e5-a05c-9503a469be08 For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units. As of the date of this press release, the Company has 12,594,758 common shares outstanding. BioSyent Inc.Interim Unaudited Condensed Consolidated Statements of Net Income and Comprehensive Income       In Canadian DollarsQ3 2021 Q3 2020 % Change YTD 2021 YTD 2020 % Change Net Revenues6,690,419 5,771,739 16%21,399,562 16,605,840 29%Cost of Goods Sold1,433,239 1,277,645 12%4,583,301 3,581,708 28%Gross Profit5,257,180 4,494,094 17%16,816,261 13,024,132 29%Operating Expenses and Finance Income/Costs3,057,582 3,191,544 -4%10,984,378 8,823,283 24%Net Income Before Taxes2,199,598 1,302,550 69%5,831,883 4,200,849 39%Tax (including Deferred Tax)478,278 346,641 38%1,428,121 1,071,216 33%Net Income After Taxes1,721,320 955,909 80%4,403,762 3,129,633 41%Net Income After Taxes % to Net Revenues26%17% 21%19% EBITDA2,293,173 1,399,781 64%6,144,581 4,460,350 38%EBITDA % to Net Revenues34%24% 29%27%  EBITDA – is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization. BioSyent Inc.Interim Unaudited Condensed Consolidated Statements of Financial Position     AS ATSeptember 30, 2021December 31, 2020% ChangeASSETS       Cash, cash equivalents and short term investments$27,101,933$25,577,7066%Trade and other receivables 3,742,588 1,815,015106%Inventory 2,469,958 2,073,56119%Prepaid expenses and deposits 479,810 307,59956%Loans receivable 419,056 -100%CURRENT ASSETS 34,213,345 29,773,88115%    Property and equipment 1,967,747 2,161,698-9%Intangible assets 895,437 1,007,822-11%Loans receivable 182,744 597,332-69%Deferred tax asset 66,058 30,481117%TOTAL NON CURRENT ASSETS 3,111,986 3,797,333-18%TOTAL ASSETS$37,325,331$33,571,21411 %    LIABILITIES AND SHAREHOLDERS’ EQUITY       CURRENT LIABILITIES$5,430,810$5,138,6746%NON CURRENT LIABILITIES 1,562,131 1,636,584-5%Long term debt – – Total Equity 30,332,390$26,795,95613%TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$37,325,331$33,571,21411% For further information please contact: Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: [email protected]: 905-206-0013Web: www.biosyent.com This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.